TransMedics Group Inc (TMDX)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $3.17B
Last updated: Nov 17, 2026 at 11:06 AM ET
TransMedics Group Inc (TMDX) Earnings: Report Dates and Results
TransMedics Group (TMDX) is expected to report earnings on Feb 22, 2027. In the quarter ended Sep 30, 2026, TransMedics Group reported EPS of $0.51, above the $0.27 estimate. It beat the EPS estimate in 4 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
TMDX has an expected report date of Feb 22, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 820.0% above the $0.05 reported for the quarter ended Dec 31, 2025.
TMDX Earnings Call
The latest TMDX earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 30 quarters below that had an estimate, TMDX beat 17, missed 12 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $203.00M, up 41.1% from $143.82M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $0.51 | $0.27 | $0.15 - $0.40 | +88.89% | Beat | -22.7% | 10 | 0 up, 2 down | Nov 5, 2026 | $203.00M |
| Jun 30, 2026 | $0.44 | $0.50 | $0.33 - $0.55 | -12.00% | Miss | -52.2% | 10 | 0 up, 4 down | Aug 4, 2026 | $189.95M |
| Mar 31, 2026 | $0.30 | $0.61 | $0.45 - $0.82 | -50.82% | Miss | -57.1% | 8 | 2 up, 3 down | May 5, 2026 | $173.93M |
| Dec 31, 2025 | $0.05 | $0.39 | $0.25 - $0.55 | -86.94% | Miss | -73.2% | 8 | 1 up, 0 down | Feb 24, 2026 | $160.76M |
| Sep 30, 2025 | $0.66 | $0.36 | $0.29 - $0.51 | +83.33% | Beat | +450.0% | 6 | 2 up, 0 down | Oct 29, 2025 | $143.82M |
| Jun 30, 2025 | $0.92 | $0.43 | $0.34 - $0.59 | +113.95% | Beat | +162.9% | 6 | 6 up, 0 down | Jul 30, 2025 | $157.37M |
| Mar 31, 2025 | $0.70 | $0.24 | $0.12 - $0.34 | +191.67% | Beat | +100.0% | 6 | 1 up, 1 down | May 8, 2025 | $143.54M |
| Dec 31, 2024 | $0.19 | $0.22 | N/A | -13.64% | Miss | +58.3% | 6 | 0 up, 4 down | Feb 27, 2025 | $121.62M |
| Sep 30, 2024 | $0.12 | $0.32 | $0.03 - $0.39 | -62.50% | Miss | +71.4% | 10 | 0 up, 0 down | Oct 28, 2024 | $108.76M |
| Jun 30, 2024 | $0.35 | $0.20 | $0.11 - $0.29 | +75.00% | Beat | N/A | 8 | 0 up, 0 down | Jul 31, 2024 | $114.31M |
| Mar 31, 2024 | $0.35 | $0.01 | -$0.33 - $0.11 | N/A | N/A | N/A | 5 | 0 up, 0 down | Apr 30, 2024 | $96.85M |
| Dec 31, 2023 | $0.12 | -$0.03 | -$0.08 - $0.08 | +500.00% | Beat | N/A | 4 | 0 up, 0 down | Feb 26, 2024 | $81.17M |
| Sep 30, 2023 | $0.07 | -$0.13 | -$0.36 - -$0.06 | +153.85% | Beat | N/A | 6 | 0 up, 0 down | Nov 6, 2023 | $66.43M |
| Jun 30, 2023 | -$0.03 | -$0.13 | -$0.27 - -$0.03 | +76.92% | Beat | N/A | 6 | 0 up, 0 down | Aug 3, 2023 | $52.47M |
| Mar 31, 2023 | -$0.08 | -$0.24 | -$0.31 - -$0.14 | +66.67% | Beat | N/A | 5 | 1 up, 1 down | May 1, 2023 | $41.55M |
| Dec 31, 2022 | -$0.21 | -$0.30 | -$0.40 - -$0.23 | +30.00% | Beat | N/A | 5 | 0 up, 0 down | Feb 22, 2023 | $31.38M |
| Sep 30, 2022 | -$0.25 | -$0.41 | -$0.47 - -$0.35 | +39.02% | Beat | N/A | 5 | 0 up, 0 down | Nov 3, 2022 | $25.68M |
| Jun 30, 2022 | -$0.41 | -$0.34 | -$0.41 - -$0.31 | -20.59% | Miss | N/A | 5 | 0 up, 0 down | Aug 1, 2022 | $20.52M |
| Mar 31, 2022 | -$0.38 | -$0.39 | -$0.44 - -$0.29 | +2.56% | Beat | N/A | 5 | 0 up, 0 down | May 3, 2022 | $15.88M |
| Dec 31, 2021 | -$0.46 | -$0.42 | -$0.45 - -$0.39 | -9.52% | Miss | N/A | 5 | N/A | Feb 23, 2022 | $9.67M |
| Sep 30, 2021 | -$0.47 | -$0.37 | -$0.49 - -$0.17 | -27.03% | Miss | N/A | 5 | N/A | Nov 9, 2021 | $5.37M |
| Jun 30, 2021 | -$0.39 | -$0.29 | -$0.35 - -$0.24 | -34.48% | Miss | N/A | 5 | N/A | Aug 5, 2021 | $8.17M |
| Mar 31, 2021 | -$0.29 | -$0.30 | -$0.35 - -$0.25 | +3.33% | Beat | N/A | 5 | N/A | May 4, 2021 | $7.05M |
| Dec 31, 2020 | -$0.23 | -$0.25 | -$0.30 - -$0.17 | +8.00% | Beat | N/A | 5 | N/A | Mar 2, 2021 | $7.63M |
| Sep 30, 2020 | -$0.19 | -$0.33 | -$0.37 - -$0.29 | +42.42% | Beat | N/A | 5 | N/A | Nov 4, 2020 | $7.09M |
| Jun 30, 2020 | -$0.36 | -$0.45 | -$0.55 - -$0.30 | +20.00% | Beat | N/A | 5 | N/A | Aug 5, 2020 | $3.39M |
| Mar 31, 2020 | -$0.42 | -$0.40 | -$0.44 - -$0.38 | -5.00% | Miss | N/A | 5 | N/A | May 6, 2020 | $7.53M |
| Dec 31, 2019 | -$0.43 | -$0.40 | -$0.42 - -$0.37 | -7.50% | Miss | N/A | 4 | N/A | Mar 2, 2020 | $6.06M |
| Sep 30, 2019 | -$0.39 | -$0.45 | -$0.56 - -$0.37 | +13.33% | Beat | N/A | 4 | N/A | Nov 6, 2019 | $7.21M |
| Jun 30, 2019 | -$0.44 | -$0.44 | -$0.47 - -$0.37 | 0.00% | In line | N/A | 4 | N/A | Aug 7, 2019 | $5.67M |
| Mar 31, 2019 | -$4.86 | -$0.98 | -$1.48 - -$0.48 | -395.92% | Miss | N/A | 2 | N/A | May 2, 2019 | $4.68M |
| Dec 31, 2018 | -$1.05 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Feb 27, 2019 | $3.54M |
| Sep 30, 2018 | -$0.25 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Dec 12, 2018 | $4.04M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $2.33, up 130.8% from the year before. It was -$1.30 for the year ended Dec 31, 2018, the oldest of the 8 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $2.33 | +130.8% |
| Dec 31, 2024 | $1.01 | +1162.5% |
| Dec 31, 2023 | $0.08 | N/A |
| Dec 31, 2022 | -$1.25 | N/A |
| Dec 31, 2021 | -$1.61 | N/A |
| Dec 31, 2020 | -$1.20 | N/A |
| Dec 31, 2019 | -$6.12 | N/A |
| Dec 31, 2018 | -$1.30 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 8,000 words across 16 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 7,989 | 16 | |
| 2026Q2 | Jun 30, 2026 | 7,153 | 16 | |
| 2026Q1 | Mar 31, 2026 | 7,365 | 16 | |
| 2025Q4 | Dec 31, 2025 | 6,415 | 13 | |
| 2025Q3 | Sep 30, 2025 | 8,443 | 17 | |
| 2025Q2 | Jun 30, 2025 | 8,507 | 14 | |
| 2025Q1 | Mar 31, 2025 | 7,055 | 13 | |
| 2024Q4 | Dec 31, 2024 | 6,636 | 10 |
2026Q3 Earnings Call
Opening remarks
Hannah Jeffrey The Gilmartin Group Representative Thanks, operator. Good afternoon, and welcome to TransMedics' Third Quarter 2026 Earnings Call. I'm joined by our President and CEO, Waleed Hassanein, and our CFO, Fernando Araujo. During this call, we will make forward-looking statements, which are based on how we see things today and are subject to various assumptions. As described in our SEC filings, actual results may differ materially due to risks and uncertainties. Our conference call remarks will also include both GAAP and non-GAAP financial results. Reconciliations between GAAP and non-GAAP measures, along with information regarding our use of forward-looking statements, can be found in today's press release and in the presentation slides available on our website. With that, I will hand the call over to Waleed.
Waleed Hassanein President and CEO Thank you, Hannah. Good afternoon, everyone, and thank you for joining TransMedics' third quarter 2026 earnings call. I'm delighted to be joined today by Fernando Araujo, our new Chief Financial Officer, who will review our third quarter financial results in detail later on this call. TransMedics has built a one-of-a-kind transplant business founded on five foundational assets that are extremely difficult to replicate. At the core is our transformative OCS technology platform, amplified by our clinical organ procurement and donor screening services and enabled by our vertically integrated logistics network and NOP digital assets. Together, they form a single integrated platform with one purpose: to increase the number of organ transplants and improve outcomes for patients worldwide. Our goal is crystal clear: to be the trusted partner to every stakeholder in organ transplantation, committed to growing transplant volumes, maximizing efficiency, and improving post-transplant clinical outcomes. We are very proud of what we've built, but we are not standing still. We firmly believe our best innings are still ahead, and this conviction is why we continue to invest in innovation-driven growth across technology, services, and digital transformation of the transplant ecosystem. I will update you on the progress of these initiatives shortly. Turning to third-quarter results. The third quarter of 2026 was the strongest in TransMedics' history for both revenue and case volume. Third-quarter highlights include total revenue of approximately $203 million, up approximately 41% year-over-year; transplant product revenue of $113 million, up approximately 29% year-over-year; and transplant service revenue of roughly $79 million, up approximately 44% year-over-year. Despite typical third-quarter seasonality, OCS Liver and Heart case volume grew both year-over-year and sequentially, modestly surpassing the all-time high levels we set in the second quarter of 2026. As our near- and midterm growth initiatives begin contributing to case volumes, we fully expect product revenue growth to accelerate further and converge with our service growth rates. TransMedics transplant logistics generated approximately $41 million in revenue, up approximately 50% year-over-year.
Frequently Asked Questions About TMDX
When is TransMedics Group's next earnings date?
TransMedics Group's next earnings report is expected for Feb 22, 2027.
Did TMDX beat earnings estimates last quarter?
Yes. TransMedics Group reported EPS of $0.51 for the quarter ended Sep 30, 2026, above the $0.27 estimate, a 88.89% surprise.
What EPS do analysts expect from TMDX next quarter?
The consensus EPS estimate for TransMedics Group for the quarter ending Dec 31, 2026 is $0.46 from 14 analysts, with estimates from $0.33 to $0.56.
How often does TMDX beat earnings estimates?
TransMedics Group beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of +39.31%.
TMDX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors